1. Short title This Act may be cited as the Purple Book Continuity Act of 2019 . 2. Public Listing Section 351(k) of the Public Health Service Act ( 42 U.S.C. 262(k) ) is amended by adding at the end the following: (9) Public listing (A) In general (i) Initial publication Not later than 60 days after the date of enactment of the Purple Book Continuity Act of 2019 , the Secretary shall publish and make available to the public electronically— (I) a list in alphabetical order of the official and proprietary name of each biological product for which a biologics license under subsection (a) or this subsection is in effect as of such date of enactment; (II) the date of licensing if the biological product is licensed after 1981 and the number of the application which was approved; and (III) whether in vitro or in vivo bioequivalence studies, or both such studies, are required for applications filed under this subsection which will refer to the biological product published. (ii) Revisions Every 30 days after the publication of the first list under clause (i), the Secretary shall revise the list to include each biological product which has been licensed under subsection (a) or this subsection during the 30-day period. (iii) Patent information When patent information has been provided by the reference product sponsor to the subsection (k) applicant respecting a biological product included on the list published under this subparagraph, the Secretary shall, in revisions made under clause (ii), include such information for such biological product. (B) Date of publication A biological product for which a license is in effect under subsection (a) or this subsection shall, for purposes of this subsection, be considered to have been published under subparagraph (A) on the later of— (i) the date of its licensing; or (ii) the date of its publication in the list that— (I) was published under this section before the initial publication of the list under subparagraph (A)